Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,570.60on 19-02-2019 at 16:30:00
Change -0.40 -0.03%
Buy 1,568.00
Sell 1,567.20
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 12,464 at 1,570.60p
Day's Volume: 4,563,805
Last Close: 1,571.00p
Open: 1,566.00p
ISIN: GB0009252882
Day's Range 1,566.00p - 1,577.80p
52wk Range: 1,269.80p - 1,648.80p
Market Capitalisation: £77,258m
VWAP: 1,570.314p
Shares in Issue: 4,919m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy*12,4641,570.6017:14:42 - 19-Feb-19
Buy*9,0041,567.61117:39:12 - 19-Feb-19
Buy*21,5131,572.97117:25:00 - 19-Feb-19
Buy*9,4341,568.59817:18:55 - 19-Feb-19
Buy*2931,570.53917:12:18 - 19-Feb-19
Buy*8981,572.71717:12:18 - 19-Feb-19
Buy*179,0261,569.01317:10:53 - 19-Feb-19
Buy*1,6291,567.80117:11:07 - 19-Feb-19
Buy*2,8381,567.79817:10:48 - 19-Feb-19
Buy*7,6761,570.73217:03:05 - 19-Feb-19

Share Price History for Glaxosmithkline

Time period:
Date Open High Low Close Volume
18th Feb 2019 (Mon)1,575.601,579.801,564.001,581.003,955,658
15th Feb 2019 (Fri)1,567.001,592.401,567.001,566.009,642,445
14th Feb 2019 (Thu)1,548.801,577.601,547.001,547.009,035,104
13th Feb 2019 (Wed)1,551.201,560.401,550.001,550.001,205,366
12th Feb 2019 (Tue)1,551.201,560.401,550.001,550.001,205,366
11th Feb 2019 (Mon)1,566.401,571.001,541.601,564.809,531,938
8th Feb 2019 (Fri)1,549.401,576.001,543.201,546.407,941,852
7th Feb 2019 (Thu)1,542.401,574.401,540.800.009,136,367
6th Feb 2019 (Wed)1,509.601,553.801,476.801,522.6010,368,916
5th Feb 2019 (Tue)1,478.801,522.601,476.601,480.008,423,261
4th Feb 2019 (Mon)1,481.801,489.801,472.801,483.404,971,919
1st Feb 2019 (Fri)1,487.001,488.401,476.201,477.205,300,160
31st Jan 2019 (Thu)1,475.801,477.801,458.001,480.8010,415,641
30th Jan 2019 (Wed)1,463.201,491.601,463.001,452.207,125,539
29th Jan 2019 (Tue)1,450.001,471.201,442.601,436.007,664,435
28th Jan 2019 (Mon)1,440.001,449.401,429.801,440.405,436,832
25th Jan 2019 (Fri)1,454.201,466.201,440.401,459.6011,205,666
24th Jan 2019 (Thu)1,476.001,479.801,456.201,475.207,986,459
23rd Jan 2019 (Wed)1,492.401,504.001,475.201,490.807,792,654
22nd Jan 2019 (Tue)1,496.801,501.201,480.001,492.004,715,647
21st Jan 2019 (Mon)1,495.201,503.601,485.801,498.603,968,467

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

FTSE Strong as Markets Wait for Service Sector News

News - Wednesday, July 05, 2017

The FTSE 100 got off to a strong start, as investors waited for the publication of the Markit Survey data, which implied that little had changed month on month for June....

Why The FTSE Didn’t Crash After Trump

News - Thursday, November 10, 2016

In the immediate aftermath of the US Presidential Election, the FTSE 100 did slip slightly, but it was not the massive crash that some had predicted. Indeed, a number of companies in the UK’s leading index made significant gains....

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered